We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.5099 | -1.15% | 43.7001 | 44.42 | 43.333 | 44.38 | 15,962,876 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Nektar Therapeutics (NKTR) and Bristol-Myers Squibb Co. (BMY) Thursday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to the combination of Nektar's bempegaldesleukin and Bristol's cancer drug Opdivo for patients with previously untreated unresectable or metastatic melanoma.
The companies said a phase 3 study evaluating the combination versus Opdivo alone in first-line advanced melanoma patients is currently recruiting patients.
Bempegaldesleukin, Nektar's lead immuno-oncology candidate, is designed to provide activation and proliferation of cancer-killing immune cells.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 01, 2019 07:44 ET (11:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
